Navigation Links
Gene therapy to lower blood pressure just enough

A newly developed virus that introduces a blood pressure-lowering gene into cells and enables that gene to maintain blood pressure at healthy levels for four months promises to take gene therapy for the disorder a step closer to reality, said researchers at Baylor College of Medicine in a report released online in the Proceedings of the National Academy of Sciences.

"High blood pressure is one of the leading causes of death and disability in adults worldwide," said Dr. Bert O'Malley, chair of the BCM department of molecular and cellular biology. "A therapy that could control blood pressure could have important benefits for individuals and for the health of the world's population as well."

The gene in question -- atrial natriuretic peptide or ANP -- promises to control blood pressure through a variety of effects on key areas involved in the problem of hypertension, including the relaxation of smooth muscle cells in blood vessels, increasing the vessels' diameters, and reducing the manner in which the vessels react to agents that can constrict those vessels. ANP also improves the manner in which the kidney eliminates sodium or salt from the body and inhibits other systems, such as the sympathetic nervous system, believed linked to development of high blood pressure.

"This makes ANP an attractive agent for use in treating blood pressure," said O'Malley. "However, its use is limited by the fact that it has such short-lived activity in the blood system."

Its activity is halved 30 seconds after it enters the blood stream.

Gene therapy can make cells generate more ANP. In previous studies, however, this kind of gene reduced blood pressure to dangerously low levels, said O'Malley. Obviously, a method of controlling the gene and the amount of ANP a cell makes was needed.

The special viral vector developed by O'Malley and his colleagues combines a special kind of adenovirus altered so it does not produce disease connected to a gene regulatory system turned on by the drug mifepristone.

Using this vector, O'Malley and his colleagues were able to introduce the ANP gene into the cells of mice. Then tiny doses of drug turned on the regulatory system, which controlled the amount of ANP made so that blood pressure remained at healthy levels for 125 days - 74 days longer than in any previous gene therapy study. Other studies indicate that the therapy could reduce the heart-weight/body-weight ratio. For this reason it has promise in reducing some of the organ damage that occurs as a result of high blood pressure.

One question that remains is whether the body will accept repeated injections of the viral vector or whether its immune system eventually react against it, said O'Malley.


'"/>

Source:Baylor College of Medicine


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee is ... honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. ... world’s leading conference and exposition for laboratory science, which will be held February ...
Breaking Biology Technology: